SciVision Biotech Inc. (TPE:1786)
Taiwan · Delayed Price · Currency is TWD 46.30
+0.40 (0.87%)
Sep 8, 2026, 1:30 PM CST
SciVision Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 889.15 | 886.62 | 883.31 | 712.99 | 557.35 | 505.54 | |
Revenue Growth | -0.23% | 0.38% | 23.89% | 27.93% | 10.25% | 8.28% |
Cost of Revenue | 261.46 | 248.23 | 227.63 | 200.49 | 185.48 | 163.7 |
Gross Profit | 627.69 | 638.39 | 655.68 | 512.49 | 371.87 | 341.84 |
Selling, General & Admin | 383.95 | 355.28 | 346.86 | 259.44 | 184.8 | 153.95 |
Research & Development | 97.34 | 93.19 | 60.71 | 53.42 | 52.46 | 65.94 |
Operating Expenses | 481.29 | 448.47 | 407.57 | 312.86 | 237.26 | 219.89 |
Operating Income | 146.4 | 189.92 | 248.11 | 199.64 | 134.61 | 121.94 |
Interest Expense | -11.8 | -7.93 | -5.67 | -8.22 | -6.46 | -8.07 |
Interest & Investment Income | 27.43 | 24.42 | 20.61 | 14.9 | 4.88 | 2.63 |
Currency Exchange Gain (Loss) | 42.92 | -19.24 | 20.48 | -0.51 | 11.81 | -1.46 |
Other Non Operating Income (Expenses) | 1.16 | 0.01 | 1.43 | 0.75 | 0.17 | 1.01 |
EBT Excluding Unusual Items | 206.11 | 187.18 | 284.96 | 206.56 | 145.02 | 116.05 |
Gain (Loss) on Sale of Investments | 1.25 | -2.13 | 6.45 | 2.9 | -1.98 | -0.13 |
Gain (Loss) on Sale of Assets | -0 | -0.01 | 0.19 | 0.54 | 30.55 | 0.13 |
Other Unusual Items | - | - | - | - | -0.04 | - |
Pretax Income | 207.36 | 185.04 | 291.6 | 210 | 173.55 | 116.06 |
Income Tax Expense | 29.25 | 22.7 | 49.34 | 32.1 | 31.83 | 14.34 |
Net Income | 178.11 | 162.34 | 242.25 | 177.9 | 141.72 | 101.72 |
Net Income to Common | 178.11 | 162.34 | 242.25 | 177.9 | 141.72 | 101.72 |
Net Income Growth | 8.89% | -32.99% | 36.17% | 25.53% | 39.32% | -20.53% |
Shares Outstanding (Basic) | 74 | 72 | 69 | 67 | 66 | 66 |
Shares Outstanding (Diluted) | 77 | 77 | 74 | 76 | 75 | 71 |
Shares Change | 2.16% | 3.33% | -2.58% | 2.39% | 5.18% | 0.61% |
EPS (Basic) | 2.42 | 2.24 | 3.51 | 2.66 | 2.14 | 1.54 |
EPS (Diluted) | 2.38 | 2.18 | 3.30 | 2.41 | 1.92 | 1.51 |
EPS Growth | 7.65% | -34.03% | 37.15% | 25.26% | 27.30% | -20.11% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 52.77 | 22.46 | 235.11 | 257.28 | 167.03 | 72.73 |
Free Cash Flow Per Share | 0.69 | 0.29 | 3.16 | 3.37 | 2.24 | 1.02 |
Dividend Per Share | 1.910 | 1.910 | 3.250 | 2.500 | 2.000 | 1.420 |
Dividend Growth | -41.23% | -41.23% | 30.00% | 25.00% | 40.84% | 60.49% |
Gross Margin | 70.59% | 72.00% | 74.23% | 71.88% | 66.72% | 67.62% |
Operating Margin | 16.46% | 21.42% | 28.09% | 28.00% | 24.15% | 24.12% |
Profit Margin | 20.03% | 18.31% | 27.43% | 24.95% | 25.43% | 20.12% |
Free Cash Flow Margin | 5.93% | 2.53% | 26.62% | 36.08% | 29.97% | 14.39% |
EBITDA | 222.9 | 260.13 | 310.17 | 261.42 | 195.35 | 173.08 |
EBITDA Margin | 25.07% | 29.34% | 35.12% | 36.66% | 35.05% | 34.24% |
D&A For EBITDA | 76.5 | 70.21 | 62.06 | 61.78 | 60.74 | 51.14 |
EBIT | 146.4 | 189.92 | 248.11 | 199.64 | 134.61 | 121.94 |
EBIT Margin | 16.46% | 21.42% | 28.09% | 28.00% | 24.15% | 24.12% |
Effective Tax Rate | 14.11% | 12.27% | 16.92% | 15.29% | 18.34% | 12.35% |